Local Injection Of OK-432 Research Articles

An adult submandibular cystic lymphangioma successfully treated with local injection of OK-432: a case report

An adult submandibular cystic lymphangioma successfully treated with local injection of OK-432: a case report

A Case of Sublingual Ranula That Responded Successfully to Localized Injection Treatment with OK-432 after Healing from Drug Induced Hypersensitivity Syndrome.

A ranula is a mucus retention cyst or pseudocyst caused by leakage of mucus from the sublingual gland and generally occurs in the oral floor. In addition, drug induced hypersensitivity syndrome (DIHS) is a rare but well-recognized serious adverse effect characterized by fever, skin rashes, generalized lymphadenopathy, hepatitis, and hepatosplenomegaly and oral stomatitis. This paper presents the first case of successfully treated sublingual ranula with localized injection of OK-432 after healing from drug induced hypersensitivity syndrome, which has previously been unreported in the literature. We present the case of a 38-year-old Japanese woman with sublingual ranula that responded successfully to localized injection treatment with OK-432 after healing from drug induced hypersensitivity syndrome. She was affected with cutaneous myositis and interstitial lung disease when she was 26 years old. At the age 34 years, she received additional oral treatment of diaminodiphenyl-sulfone due to deterioration of the cutaneous myositis, which resulted in drug induced hypersensitivity syndrome (DIHS) with severe oral stomatitis. Local injection of OK-432 to the ranula may be a very safe and useful treatment method even if the patient has a history of drug allergy and has connective tissue disease such as cutaneous myositis.

OK432の局注療法が奏功した翼突下顎隙囊胞状リンパ管腫の1例

OK432の局注療法が奏功した翼突下顎隙囊胞状リンパ管腫の1例

OK-432局所注入による小児のBlandin-Nühn嚢胞の治療経験

OK-432局所注入による小児のBlandin-Nühn嚢胞の治療経験

Successful treatment of recurrent abdominopelvic neurenteric cysts by OK-432 injection

The case of recurrent intraabdominal neurenteric cyst after surgical excision in an infant is described. After several operative resections, we changed therapeutic strategy and performed local injection of OK-432. Indeed, there is experience with the application of OK-432 for other entities, especially lymphangioma, but to our knowledge, there is no report published so far on the treatment of neurenteric cyst with OK-432. We describe for the first time an effective and simple treatment of recurrent neurenteric cyst.

Myxofibrosarcoma of the neck

We report a rare case of myxofibrosarcoma arising in the neck. A 55-year-old man presented with a two-year history of left-sided, painless, submandibular swelling. Computed tomography and magnetic resonance imaging (MRI) revealed an 80 x 35 mm, well defined, lobulated, submandibular tumour extending to the parapharyngeal space. The tumour showed uniformly low intensity and marked hyperintensity in T1- and T2-weighted MRI scans, respectively, and was scarcely enhanced by gadolinium. A tentative diagnosis of lymphangioma or plunging ranula was made, and the patient underwent local injection of OK-432, which proved to be ineffective. Resection of the tumour was then performed via a transcervical approach. The tumour was histopathologically and immunohistochemically diagnosed as a low-grade myxofibrosarcoma. The patient's post-operative clinical course was uneventful, and the patient was free of disease 27 months after surgery. The pathology, clinical characteristics and treatment of myxofibrosarcoma are bibliographically reviewed.

Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.

The accumulation of T cells into the tumor site is crucial for the elicitation of in vivo antitumor effects after cancer vaccination. In this study, we investigated the antitumor effects and associated mechanisms of action that were induced by systemic and local immunization with a CTL-directed peptide in combination with a peritumoral injection of a streptococcal preparation, OK-432. The human SART3(315-323) peptide, which has the potential to induce human leukocyte antigen-A24-restricted CTLs, not only has the same amino acid sequence as the mouse SART3, but also has the capacity for binding to H-2K(d) molecules. Therefore, the SART3(315-323) peptide could be used as a tumor antigen-derived peptide in H-2(d) mice. Systemic immunization with the SART3(315-323) peptide and the subsequent peritumoral injection of both the SART3(315-323) peptide and OK-432 effectively induced peptide-specific and colon26 carcinoma-reactive CTLs in BALB/c mice. The combination therapy suppressed the growth of s.c. established colon26 carcinoma. The accumulation of both CD8(+) and CD4(+) T cells into the tumor site was more apparent in mice treated with the combination therapy than in those treated with other protocols. In addition, the level of IgG reactive to the administered SART3(315-323) peptide increased in mice that were treated with the combination therapy. These results indicate that antitumor effects could be efficiently induced by a combination therapy that included systemic and local immunization with a CTL-directed peptide together with a local injection of OK-432.

Efficacy of OK-432 local injection for the treatment of a neonatal branchial cleft cyst: a case report

We herein present a case of a neonatal cervical cyst, which was diagnosed prenatally, and markedly decreased in size and disappeared after a local injection therapy of OK-432. A 0-day-old boy had an abnormal prenatal ultrasonography scan suggestive of rt. cervical cyst, measuring about 25 mm in diameter at 29 weeks' gestation. At birth, an elastic soft mass, measuring about 30 mm in diameter, was found on the right side of his neck. Computed tomography (CT) scans showed a giant cyst, which extended from the upper level of epipharynx to the upper mediastinum, and the contents were air and fluid. At 20 days of age, ultrasonography (US)-guided needle aspiration was performed. The aspirated fluid contained no epithelial cells, but many lymphocytes and neutrophils based on a cytological analysis. After the local injection of OK-432 had been performed four times, the right neck cyst had almost completely disappeared on US scans. During the local injection therapy, we analyzed the other sample of the second aspiration fluid of the neck cyst. Several clusters of epithelial cells, columnar epithelium, squamous cells, and ciliated epithelium were thus cytologically observed. Therefore, a final diagnosis of a branchial cleft cyst was made. The local injection of OK-432 was thus found to be an effective treatment for branchial cleft cysts.

Six cases of children with a benign cervical tumor who required tracheostomy

Cervical tumors sometimes cause airway obstruction. We have treated six children with benign cervical tumors who required tracheostomy. Two cervical and one glossal lymphangiomata treated with local injection of OK432 after creating a tracheostomy were successfully decannulated after the treatment. One patient with a giant cervical lymphangioma needed an EXIT (ex utero intrapartum treatment) procedure. He underwent tracheostomy at 10 months of age after long-term endotracheal intubation, but he died of sepsis and hypoxic brain damage at 18 months. One patient with a subglottic hemangioma treated with steroids finally achieved closure of the tracheostomy at 2 years of age. A 7-year-old girl with a tracheal schwannoma underwent tracheostomy performed a week after admission, but she already had hypoxic brain damage resulting from problems with intubation. Most patients with a lymphangioma or hemangioma in the cervical region have required early tracheostomy before commencing treatment with OK-432 or steroids. If there is any sign of possible airway compromise, then it is vital to perform an early tracheostomy, even for benign tumors.

Local Injection of OK-432 in the Treatment of Ranula: A Case Report

We treated a 57-year-old woman for ranula. After aspirating the cyst's contents, we administered 0.1 KE/ml of OK-432 via local injection. One month later, the cyst had still persisted, so we repeated the procedure. After 2 weeks, the ranula began to shrink markedly, and at 4 weeks it had almost disappeared. No recurrence of the ranula was observed during the subsequent 1 year of follow-up. Following each injection, the patient developed transient fever and local swelling but no serious complications. Our experience suggests that OK-432 injection is an effective treatment for ranula. However, because this treatment causes the cyst to collapse rather than disappear completely, patients should be regularly monitored over the long term.

頚部嚢胞状リンパ管腫の４症例

Four patients with cervical cystic lymphangioma were treated in our clinic. Three patients were surgically treated. In 2 of these patients, tumors were completely removed. These tumors showed no invasion of the oral floor, parapharyngeal space or sphenopalatine fossa. A tumor in the third patient could not be completely resected. The tumor had invaded the oral floor, parapharyngeal space and sphenopalatine f ossa. In this patient, the volume of the remaining tumor was decreased postoperatively by local injection of OK-432. One patient did not undergo surgery, and was treated with local injection of OK-432 as the first choice. Since this therapy the tumor has not been palpable. These results suggest that local injection of OK-432 may be the first choice in place of surgical treatment for cases in which incomplete resection or postoperative complications are predicted.

A case of cystic lymphangioma in a child treated with local injection of OK-432

A case of cystic lymphangioma in a child treated with local injection of OK-432

Local injection of OK-432 in cystic hygroma: a report of 2 cases

Local injection of OK-432 in cystic hygroma: a report of 2 cases

Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential.

The effect of local injections with streptococcal preparation OK432 on the therapeutical potential of tumor-draining lymph node (LN) cells was investigated in mice. Peritumoral injections with OK432 on days 2, 4, 6, 8 and 10 showed no effect on the in vivo growth of s.c. inoculated B16F10 melanoma. The B16F10-draining OK432-treated LN cells, however, showed a high level of anti-B16F10 cytolytic activity after an in vitro culture first with both anti-CD3 monoclonal antibody (MAb) and activated B cell blasts, and subsequently with interleukin (IL)-2 without in vitro restimulation. Such in vitro expanded LN cells showed a remarkable antitumor effect against pulmonary metastasis of B16F10 melanoma, even without the concurrent administration of IL-2. In addition, the therapeutical protocol was also found to be moderately effective against poorly immunogenic MCA fibrosarcoma, and the in vivo antitumor effect was specific to the tumor from which the LNs were harvested. Interestingly, 2 kinds of comparative analyses of the cytokines revealed that the B16F10-bearing state induced the draining LN cells to develop a Th2-type response. However, the OK432 treatment was able to effectively augment their Th1-type response. Collectively, our results suggest that peritumoral injections with OK432 significantly increased the therapeutical potential of the tumor-draining LN cells by augmenting their Th1-type response.

高齢者胆囊癌に対する腹腔鏡下胆囊摘出術および術中OK-432局注療法の経験

高齢者胆囊癌に対する腹腔鏡下胆囊摘出術および術中OK-432局注療法の経験

Local injection of OK-432/Fibrinogen gel into head and neck carcinomas

Immunotherapy with biological response modifiers (BRM) is a possible strategy against head and neck solid tumours. However, the: rapid disappearance of BRM from the tumour area is one of the reasons for its limited clinical application. In this pilot study, fibrinogen gel containing OK-432 (a compound composed of attenuated Streptococcus pyogenes), an inducer of natural killer cells and T-cell cytotoxity, was injected directly into head and neck solid tumours of 15 patients. A dose of 5 Klinische Einheiten (KE) of OK-432 was reconstituted in 1 ml aprotinin and mixed with fibrinogen, the latter to maintain the OK-432 locally. 3 patients showed tumour regression, and in addition, we observed histological changes in the injected tumour of all patients. These results suggest that OK-432/fibrinogen gel generates a local immune response, leading to tumour regression.

ＯＫ‐４３２溶解液とリピオドールとの混合液のエマルジョン化の判定

We have been attempting local injection of OK-432 in a lymph node or its surrounding areas in patients with lymph node metastases when we confirmed that the patients had relapse. We mixed OK-432 solution and lipiodol. After injection of this mixture, we examined the extent of infiltration of this mixture with fluoroscopy, We checked whether this mixture was actually in the state of emulsion. Immediately after mixing them, a single water phase was observed, and three hours later, two phases were already separated as determined by a visual inspection. However, at this stage, majority of the cases were in the state of emulsification. These findings may indicate that the mixture was in emulsion at the time of injection, and that it gradually degraded successively in the body. However, we speculate that it might be possible to achieve more stable emulsion by the use of surfactants or by adjusting differences in the specific gravities of two phases.

頭頸部悪性腫瘍に対するOK-432局注の組織学的効果

Local injection of OK-432 was performed on 5 patients with malignant head and neck tumors. Even though the tumor was relatively small, neither surgical resection nor aggressive chemotherapy was indicative in any of these patient.Locally, cicatrizations were observed after severe inflammatory reactions. Lymph nodes persisted as indurations and did not disappear until the end.Histologically, tumor cells were not noticed from samples o btatined after treatment. With this method of treatment, curative therapy is possible against relatively small tumors.

OK-432局所注射使用経験(第1報)

Tomomi Itaya, Isato Tsuge, Toshio Kimura, Yasuhiro Ito, Masakazu Kouketsu and Syunkichi Baba (Nagoya City University Medical School)The relationship between the HLA type and disease has been reported by many authors. Watanabe (1983) reported that patients with HLA B5 (BW51, BW52) were considered to be highly responsive to OK-432.We used local injection of OK-432 in 4 cases of head and neck tumor, and investigated the relationship between their respose and the HLA type, clinically and histologically.Among our cases, we could not find any patients with HLA B5 highly responsive to OK-432. However, it is useful to know the responsiveness of OK-432 before treatment.